MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

BC-LI-0186

CAS No. : 695207-56-8

MCE 站：BC-LI-0186

产品活性：BC-LI-0186 是一种有效的选择性亮氨酸 tRNA 合成酶 (Leucyl-tRNA synthetase (LRS)) 与 Ras 相关的 GTP 结合蛋白 D (RagD) 相互作用的抑制剂 (IC₅₀=46.11 nM)。BC-LI-0186 与 LRS 的 RagD 相互作用位点 (K_d=42.1 nM) 竞争，并对 LRS- vps34、LRS- eprs、RagB-RagD 缔合、mTORC1 复合物的形成没有产生影响。BC-LI-0186 能有效抑制肿瘤相关 MTOR 突变体的活性和雷帕霉素耐药癌细胞的生长。BC-LI-0186 可用于肺癌的相关研究。

研究领域：Metabolic Enzyme/Protease

作用靶点：Aminoacyl-tRNA Synthetase

In Vitro: BC-LI-0186 (0-20 μM; starved for 90?min in the leucine-free medium and then in the serum-free media for 15?min) inhibits phosphorylation of S6K in a dose- and time-dependent manner, but it has no effects on hosphorylation of AKT (S473).
BC-LI-0186 (0-20 μM; 6 hours) induces cleaved poly (ADP-ribose) polymerase (PARP) and caspase-3 and an increase of p62 in A549 and H460 cells.
BC-LI-0186 exhibits cytotoxic effect at nanomolar concentration in NSCLC cells, it exhibits IC₅₀ values of 98 nM, 206 nM, 55 nM,?78 nM, 83 nM, 86 nM, 102? nM, 109?nM, 128 nM, and 206 nM in A549, H460, H2228, H1703, SNU1330, H1650, H2009, H358, H2279, H460, and H596 cells, respectively.
BC-LI-0186 overcome acquired rapamycin resistance and inhibits the mTORC1 pathway in isogenic HCT116 cell lines that harbored either?M TOR WT (HCT116 MW) or S2035I mutations (HCT116 MM), it exhibits little changed efficacy between the wild-type and mutant cells (GI₅₀: 39.49 ?nM and 42.03?nM, EC₅₀: 105.03 nM and 100.45 ?nM).

In Vivo: BC-LI-0186 (intraperitoneal?injection; 50?mg/kg; alone or combines with cisplatin alone; 2 weeks; bid for 5?days per week) exhibits antitumor effects and significantly reduces tumor size compared with treatment with vehicle in an LSL K-ras G12D lung cancer animal model.

相关产品：Asp-AMS  |  Aminoacyl tRNA synthetase-IN-1  |  Arg-AMS  |  Gln-AMS TFA  |  GlyRS-IN-1  |  Leu-AMS

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。